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It remains unclear whether any aspect of quality of life has a role in predicting survival in an unselected cohort of patients with gastro-
oesophageal cancer. Therefore the aim of the present study was to examine the relationship between quality of life (EORTC QLQ-
C30), clinico-pathological characteristics and survival in patients with gastro-oesophageal cancer. Patients presenting with gastric or
oesophageal cancer, staged using the UICC tumour node metastasis (TNM) classification and who received either potentially curative
surgery or palliative treatment between November 1997 and December 2002 (n¼152) participated in a quality of life study, using
the EORTC QLQ-C30 core questionnaire. On univariate analysis, age (Po0.01), tumour length (Po0.0001), TNM stage
(Po0.0001), weight loss (Po0.0001), dysphagia score (Po0.001), performance status (Po0.1) and treatment (Po0.0001) were
significantly associated with cancer-specific survival. EORTC QLQ-C30, physical functioning (Po0.0001), role functioning (Po0.001),
cognitive functioning (Po0.01), social functioning (Po0.0001), global quality of life (Po0.0001), fatigue (Po0.0001), nausea/vomiting
(Po0.01), pain (Po0.001), dyspnoea (Po0.0001), appetite loss (Po0.0001) and constipation (Po0.05) were also significantly
associated with cancer-specific survival. On multivariate survival analysis, tumour stage (Po0.0001), treatment (Po0.001) and
appetite loss (Po0.0001) were significant independent predictors of cancer-specific survival. The present study highlights the
importance of quality of life (EORTC QLQ-C30) measures, in particular appetite loss, as a prognostic factor in these patients.
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Gastro-oesophageal cancer is the third commonest cause of cancer
death in the UK. Each year, there are approximately 16500 new
cases and over 13000 deaths attributable to the disease. Overall
survival is poor with the majority of patients presenting with
advanced, inoperable disease and less than 15% surviving 5 years
(Cancer Research UK, Information Resource Centre, 2004).
Although there have been improvements in survival following
surgery (Ando et al, 2000; Hundahl et al, 2000; Hofstetter et al,
2002; von Rahden and Stein, 2004), for the majority of patients
current treatment offers little in terms of improved survival. As a
result quality of life in these patients is likely to be of considerable
importance (Aaronson, Bullinger and Ahmedzai, 1988; Aaronson
et al, 1993).
The European Organisation for Research and Treatment of
Cancer have developed and validated the EORTC-QLQ-C30
questionnaire designed to assess the quality of life of cancer
patients (Aaronson et al, 1993). Disease-specific aspects of the
questionnaire provide detailed information about the patients’
perception of their health. Moreover, it has been reported that, in a
few studies, the EORTC QLQ-C30 measurement of quality of life
may have prognostic value in patients with gastro-oesophageal
cancer (Conroy et al, 2006).
Blazeby et al, (2001) reported that, in addition to age and TNM
stage, physical function or emotional function had independent
prognostic value in 92 patients with oesophageal cancer. However,
treatment (whether or not the patient underwent surgery) was not
included in the model (Blazeby et al, 2001).
Fang et al (2004) studied 110 patients with squamous
oesophageal cancer and concluded that there was evidence to
support the correlation of patient-reported quality of life scores
with survival; therefore, pretreatment physical functioning might
be a surrogate marker of an unrecognised biological prognostic
factor. Although performance status was significant on univariate
analysis, it was not significant on multivariate analysis; whereas
physical functioning was significant (Fang et al, 2004).
In contrast, in a study of more than 1000 patients with
inoperable gastro-oesophageal cancer, entering three randomised
clinical trials, Chau et al (2004) reported that no aspect of the
QLQ-C30 had independent prognostic value when performance
status was considered. However, physical function, role function
and global quality of life were associated with survival on
univariate analysis. There were no survival differences among
patients with oesophageal or gastric cancer (Chau et al, 2004).
However, this study was retrospective and included selected
cohorts of patients.
Therefore, from the above it remains unclear whether any aspect
of quality of life other than physical function has a role in
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spredicting survival in an unselected cohort of patients with gastro-
oesophageal cancer. The aim of the present study was to examine
the relationship between quality of life (EORTC QLQ-C30),
clinico-pathological characteristics and survival in patients with
gastro-oesophageal cancer.
PATIENTS AND METHODS
Patients
Patients presenting with adenocarcinoma or squamous carcinoma
of the gastric or oesophageal tract at the Royal Infirmary and
Southern General Hospital, Glasgow between November 1997 and
December 2002 (n¼152) participated in a quality of life study,
using the EORTC QLQ-C30 core questionnaire.
The extent of tumour spread was recorded using the TNM
5th edition classification (Sobin and Wittekind, 1997).
Tumours around the gastro-oesophageal junction were
further classified according to tumour site, using the Siewert
system; type 1 and 2 lesions of the gastro-oesophageal junction
were designated as cancers of the oesophagus. Type 3 tumours of
the cardia were designated as gastric cancers (Siewert and Stein,
1998).
For gastric cancers, TNM stage I–III tumours were considered
to be potentially amenable to curative surgical resection. For
oesophageal cancers, TNM stage I–III tumours, excluding T4, were
deemed to be potentially amenable to curative surgical resection.
Patients who had stage 1 and 2 disease but whose performance
status was poor or who had significant comorbidity were deemed
not suitable for surgery and went forward for active palliative
treatment or supportive care. There were 152 patients included in
the study, 69 patients underwent surgery and 83 patients received
active palliative treatment or supportive care.
The study was approved by the Research Ethics Committee of
the Royal Infirmary and Southern General Hospital, Glasgow.
Methods
Clinical and demographic variables were recorded at the patient’s
initial presentation and included age, sex, tumour type, site and
length, TNM stage, ECOG performance status, weight loss and
dysphagia.
Following diagnosis but prior to treatment the lead clinician
approached patients as to whether they would participate in a
study to examine their quality of life. If they gave informed consent
they were given the EORTC QLQ-C30 questionnaire to complete.
Different aspects of quality of life were assessed using this
cancer-specific 30-item questionnaire, which has six functional
scales (physical, role, emotional, cognitive, social, global health
status) and several questions relating to a range of physical
symptoms (Aaronson et al, 1993). Patients marked to what extent
each statement applied to them. A number of patients were
excluded because they were unlikely to understand the ques-
tionnaire either due to language, brain metastases, delirium or
confusion. Neither age nor performance status were considered
when offering the patient questionnaire. Few subjects were
excluded (less than 10 patients) and therefore in those patients
offered the questionnaire the bias was likely to be small.
Statistics
Scoring algorithms have been produced by the EORTC Quality of
Life Study Group. The sum of items in each category is added and
the total divided by the number of questions in the category.
A linear transformation is then undertaken to convert this to a
percentage scale with a higher score representing a higher
response level. Thus a high score for functional scale represents
a high/healthy level of functioning. A high score for the global
health status/quality of life represents a high quality of life. In
contrast, a high score for the symptom scale represents a higher
level of symptoms/problems (Aaronson et al, 1993).
Data are presented as the median and range. Survival was
determined from the time of biopsy proven diagnosis, and the end
point for survival analysis was cancer-specific death. Patients were
followed up at their clinic or endoscopy appointments and
information on date and cause of death was checked with that
received by the cancer registration system through the Registrar
General (Scotland). Deaths up to the end of April 2007 were
included in the analysis.
Univariate and multivariate survival analysis and calculation of
hazard ratios (HR) were performed using a Cox regression model.
For simplicity of presentation, a single hazard ratio was calculated
for each ordered categorical variable, corresponding to the relative
risk between adjacent categories. Hazard ratios for EORTC quality
of life and symptom scores relate to a one percentage point
increase in the score. Owing to the large number of covariates
examined, only those that were significant on univariate analysis
were included in the multivariate analysis, and only main effects
were considered. The analysis was performed using a backward
stepwise procedure to derive a final model of the variables that had
a significant relationship with survival. To remove a variable from
the model, the corresponding P-value had to be greater than 0.05.
The proportional hazards assumption was checked using log
minus log plots.
Comparison of the association between tumour site, TNM stage,
treatment and the functional (physical, role, emotional, cognitive,
social, global health status) and physical symptoms (fatigue, pain
and appetite loss) scales of the EORTC-QLQ-C30 quality of life
questionnaire was carried out using the w
2-test or Mann–Whitney
U-test where appropriate. Analysis was performed using SPSS
software (SPSS Inc. Chicago, IL, USA).
RESULTS
Patient characteristics and cancer specific survival analysis of
patients with gastro-oesophageal cancer (n¼152) are shown in
Table 1. The minimum follow-up period was 54 months or until
date of death, the median follow-up for survivors was 81 months,
one patient was lost to follow up and one patient withdrew from
the study. During this period 106 (70%) patients died from their
disease and 14 (9%) died from comorbid disease.
The majority of patients were over the age of 65 years (57%),
male (68%) and had adenocarcinomas (84%). The majority of
patients presented with weight loss (66%), had little or no
dysphagia and a near normal performance status (ECOG-ps,
71%). The majority of patients had EORTC QLQ-C30 function
scores above 50 (physical functioning 100%, role functioning 65%,
emotional functioning 74%, cognitive functioning 83%,
social functioning 79% and global quality of life 56%) and
symptom scores below 50 (fatigue 69%, nausea/vomiting 85%,
pain 86%, dyspnoea 79%, sleep disturbance 69%, appetite loss
64%, constipation 76%, diarrhoea 95% and financial diffi-
culties 89%) and therefore had apparently normal quality of life
(Table 1).
On univariate analysis, age (Po0.01), tumour length
(Po0.0001), TNM stage (Po0.0001), weight loss (Po0.0001),
dysphagia score (Po0.001), performance status (Po0.1) and
treatment (Po0.0001) were significantly associated with cancer-
specific survival. EORTC QLQ-C30, physical functioning
(Po0.0001), role functioning (Po0.001), cognitive functioning
(Po0.1), social functioning (Po0.0001), global quality of life
(Po0.0001), fatigue (Po0.0001), nausea/vomiting (Po0.01), pain
(Po0.001), dyspnoea (Po0.0001), appetite loss (Po0.0001) and
constipation (Po0.01) were also significantly associated with
cancer-specific survival.
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(Po0.0001) and appetite loss (Po0.0001) were significantly
independent predictors of cancer-specific survival. The relation-
ship between appetite loss and cancer-specific survival in patients
with gastro-oesophageal cancer is shown in Figure 1.
When appetite loss was rescaled so that the four categories were
represented by an integer score of 0 to 3 (rather than a percentage
score), the unadjusted hazard ratio comparing adjacent categories
was 2.06 (95% CI 1.72–2.48, Po0.0001). When adjusted for stage
and treatment, it was 1.72 (95% CI 1.41–2.08, Po0.0001). When
adjusted for stage, treatment and remaining clinico-pathological
variables, it was 2.07 (95% CI 1.61–2.67, Po0.0001). When
adjusted for stage, treatment, remaining clinico-pathological
variables and quality of life and symptom scores, it was 2.03
(95% CI 1.40–2.94, P¼0.0002).
In the present study C-reactive protein concentrations, at the
time of quality of life assessment, were available in 94 patients
(57 patients o10mgl
 1, 37 patients 410mgl
 1) and were
significantly associated with poorer cancer-specific survival
(Po0.0001). Therefore we included C-reactive protein in addition
to TNM stage, treatment and appetite loss in the multivariate
survival model. TNM stage (HR 1.37, 95% CI 1.01–1.87,
P¼0.0426), treatment (HR 3.67, 95% CI 1.74–7.75, P¼0.0006),
appetite loss (HR 1.02, 95% CI 1.01–1.03, Po0.0001) and C-
reactive protein (HR 2.15, 95% CI 1.21–3.83, P¼0.0091) were
independently associated with cancer-specific survival.
The relationship between tumour site, clinico-pathological
characteristics and quality of life in patients with gastro-
oesophageal cancer is shown in Table 2. Compared with the
gastric cancer patients, oesophageal cancer patients were older
(Po0.01), had more dysphagia (Po0.001) and a poorer ECOG-ps
(Po0.05). In terms of quality of life, compared with the gastric
cancer patients, oesophageal cancer patients had higher emotional
functioning (Po0.01), cognitive functioning (Po0.05), less nausea
and vomiting (Po0.05).
The relationship between TNM stage and clinico-pathological
and quality of life characteristics in patients with gastric-
oesophageal cancer is shown in Table 3. With increasing TNM
stage patients had greater weight loss (Po0.01) and were less likely
to have had surgery (Po0.001). In terms of quality of life, with
increasing TNM stage there was poorer physical functioning
(Po0.05), emotional functioning (Po0.05), social functioning
(Po0.01) and global quality of life (Po0.01). In terms of
symptoms, with increasing TNM stage there was more fatigue
(Po0.01), appetite loss (Po0.001), dyspnoea (Po0.05) and
constipation (Po0.05).
Table 1 The relationship between clinico-pathological characteristics, quality of life and cancer-specific survival in patients with gastro-oesophageal cancer
(n¼152)
Patients
(n¼152)
Univariate analysis HR
(95%CI) P-value
Multivariate analysis HR
(95%CI) P-value
Age: (o65/65–74/X75) 66/56/30 1.46 (1.14–1.89) 0.0033
Sex: (male/female) 104/48 0.84 (0.55–1.30) 0.4377
Tumour type: (adeno/squamous) 127/25 1.40 (0.83–2.36) 0.2016
Tumour site: (oesophagus/gastric) 70/82 0.88 (0.60–1.29) 0.5163
Tumour length: (o5/510/410cm) 60/70/12 2.37 (1.71–3.27) o0.0001
TNM stage: (I/II/III/IV) 28/46/34/41 2.29 (1.84–2.83) o0.0001 1.65 (1.25–2.18) o0.0004
Weight loss: (no/yes) 51/101 3.08 (1.94–4.89) o0.0001
Dysphagia score: (1/2/3/4/5) 81/23/32/15/1 1.37 (1.16–1.63) 0.0003
ECOG: (0–1/2/3–4) 108/38/6 1.61 (1.14–2.27) 0.0069
Treatment: (operable/inoperable) 69/83 8.12 (5.06–13.03) o0.0001 5.29 (2.80–9.97) o0.0001
EORTC QLQ-C30 (0–100) Median (range)
Physical functioning 93 (66.7–100) 0.96 (0.94–0.98) 0.0001
Role functioning 66.7 (0–100) 0.99 (0.99–1.00) 0.0006
Emotional functioning 66.7 (0–100 1.00 (0.99–1.00) 0.1302
Cognitive functioning 83.3 (0–100) 0.99 (0.98–0.99) 0.0051
Social functioning 83.3 (0–100) 0.99 (0.98–0.99) o0.0001
Global quality of life 50 (0–100) 0.98 (0.97–0.99) o0.0001
Fatigue 33.3 (0–100) 1.02 (1.01–1.02) o0.0001
Nausea and vomiting 16.7 (0–100) 1.01 (1.00–1.02) 0.0067
Pain 16.7 (0–100) 1.01 (1.01–1.02) 0.0002
Dyspnoea 0 (0–100) 1.01 (1.01–1.02) 0.0001
Sleep disturbance 33.3 (0–100) 1.00 (0.99–1.01) 0.1558
Appetite loss 33.3 (0–100) 1.02 (1.02–1.03) o0.0001 1.02 (1.01–1.03) o0.0001
Constipation 33.3 (0–100) 1.01 (1.00–1.02) 0.0007
Diarrhoea 0 (0–100) 1.00 (0.99–1.01) 0.9586
Financial difficulty 0 (0–100) 1.01 (1.00–1.01) 0.0932
Survival (months)
60 54 48 42 36 30 24 18 12 6 0
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Figure 1 The relationship between appetite loss (None, A little, Quite a
bit, Very much, from top to bottom) and cancer specific survival in patients
with gastro-oesophageal cancer.
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sThe relationship between appetite loss, clinico-pathological
characteristics and quality of life in patients with gastric-
oesophageal cancer is shown in Table 4. Increasing appetite loss
was associated with greater tumour length (Po0.05), TNM stage
(Po0.001) and the operability of the tumour (Po0.001). Also,
increasing appetite loss was associated with weight loss (Po0.001)
and dysphagia (Po0.001). In terms of quality of life, increasing
appetite loss was associated with poorer physical (Po0.001), role
(Po0.001), emotional (Po0.01), cognitive (Po0.01), social
(Po0.001) and global quality of life (Po0.001) functioning.
In terms of symptoms, with increasing appetite loss there was
more fatigue (Po0.01), nausea and vomiting (Po0.001), pain
(Po0.001), sleep disturbance (o0.05) and constipation
(Po0.001).
Table 2 The relationship between tumour site, clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer (n¼152)
Gastric (n¼82) Oesophageal (n¼70) P-value
Age: (o65 years/ 65–74 years/X75 years) 41/29/12 25/27/18 0.0041
Sex: (male/female) 53/29 51/19 0.279
Type: (squamous/adeno) 1/81 24/46 o0.001
Tumour length: (o5cm/5–10cm/410cm) 33/33/7 27/37/5 0.724
Tumour stage: (I/II/III/IV) 22/13/18/28 6/33/16/13 0.528
Dysphagia score: (1/2/3/4/5) 64/9/8/1/0 17/14/24/1 o0.001
Weight loss: (yes/no) 53/29 48/22 0.610
ECOG: (0–1/2/3–4) 64/17/1 44/21/5 0.018
Treatment: (operable/inoperable) 38/44 31/39 0.800
EORTC QLQ-C30 (0–100) Median (range) Median (range)
Physical functioning 93.3 (66.7–100) 93.3 (66.7–100) 0.733
Role functioning 66.7 (0–100) 66.7 (0–100) 0.923
Emotional functioning 66.7 (0–100) 83.3 (0–100) 0.007
Cognitive functioning 83.3 (0–100) 83.3 (0–100) 0.038
Social functioning 83.3 (0–100) 75 (0–100) 0.964
Global quality of life 50 (0–100) 50 (0–100) 0.284
Fatigue 33.3 (0–100) 22.2 (0–100) 0.077
Nausea and vomiting 16.7 (0–100) 0 (0–100) 0.036
Pain 16.7 (0–100) 16.7 (0–100) 0.716
Dyspnoea 33.3 (0–100) 0 (0–100) 0.123
Sleep disturbance 33.3 (0–100) 33.3 (0–100) 0.360
Appetite loss 33.3 (0–100) 33.3 (0–100) 0.624
Constipation 33.3 (0–100) 33.3 (0–100) 0.031
Diarrhoea 0 (0–100) 0 (0–100) 0.802
Financial difficulty 0 (0–100) 0 (0–66.7) 0.098
Table 3 The relationship between TNM stage and clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer
(n¼149)
TNM I (n¼28) TNM II (n¼46) TNM III (n¼34) TNM IV (n¼41) P-value
Age: (o65 years/ 65–74 years/X75 years) 15/12/1 23/21/2 18/9/7 18/13/10 0.482
Sex: (male/female) 17/11 33/13 20/14 31/10 0.387
Tumour type: (squamous/adeno) 2/26 13/33 6/28 4/37 0.576
Tumour site: (oesophagus/gastric) 6/22 33/13 16/18 13/28 0.528
Tumour length: (o5cm/5–10cm/410cm) 19/7/0 21/22/3 10/19/3 8/22/6 o0.001
Weight loss: (yes/no) 14/14 29/17 23/11 34/7 0.004
Dysphagia score: (1/2/3/4/5) 22/3/3/0/0 20/10/9/7/0 14/5/9/5/1 23/5/10/3/0 0.130
ECOG: (0–1/2/3–4) 22/6/0 33/11/2 27/6/1 24/15/2 0.099
Treatment: (operable/inoperable) 25/3 26/20 15/19 1/40 o0.001
EORTC QLQ-C30 (0–100) Median (range) Median (range) Median (range) Median (range)
Physical functioning 93.3 (73.3–100) 100 (66.7–100) 100 (73.3–100) 86.7 (66.7–100) 0.023
Role functioning 66.7 (0–100) 66.7 (0–100) 66.7 (0–100) 50 (0–100) 0.058
Emotional functioning 66.7 (8.3–100) 75 (25–100) 83.3 (0–100) 58.3 (0–100) 0.042
Cognitive functioning 83.3 (50–100) 83.3 (33.3–100) 83.3 (16.7–100) 75 (0–100) 0.042
Social functioning 100 (33.3–100) 83.3 (0–100) 66.7 (0–100) 50 (0–100) 0.002
Global quality of life 66.7 (8.3–100) 66.7 (0–100) 50 (16.7–100) 41.7 (0–100) 0.001
Fatigue 27.8 (0–66.7) 22.2 (0–88.9) 33.3 (0–100) 55.6 (0–100) 0.002
Nausea and vomiting 16.7 (0–100) 0 (0–100) 16.7 (0–100) 16.7 (0–100) 0.553
Pain 16.7 (0–66.7) 16.7 (0–100) 33.3 (0–100) 16.7 (0–100) 0.098
Dyspnoea 16.7 (0–100) 0 (0–100) 0 (0–100) 33.3 (0–100) 0.014
Sleep disturbance (0–100) 33.3 (0–100) 33.3 (0–100) 66.7 (0–100) 0.689
Appetite loss 0 (0–100) 33.3 (0–100) 33.3 (0–100) 66.7 (0–100) o0.001
Constipation 33.3 (0–66.7) 16.7 (0–100) 0 (0–100) 33.3 (0–100) 0.013
Diarrhoea 0 (0–100) 0 (0–100) 0 (0–33.3) 0 (0–66.7) 0.601
Financial difficulty 0 (0–66.7) 0 (0–100) 0 (0–66.7) 0 (0–100) 0.306
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as evidenced by elevated C-reactive protein, clinico-pathological and
quality of life characteristics in patients with gastric-oesophageal
cancer is shown in Table 5. An elevated C-reactive protein was
associated with greater tumour length (Po0.01), advanced TNM
stage (Po0.01) and the operability of the tumour (Po0.001) and a
poorer ECOG-ps (Po0.05). In terms of quality of life, an elevated
C-reactive protein was associated with poorer physical (Po0.01),
role (Po0.05) and social (Po0.05) functioning. In terms of
symptoms, with an elevated C-reactive protein was associated with
more fatigue (Po0.01), pain (Po0.05) and appetite loss (Po0.01).
DISCUSSION
In the present study tumour site was not associated with major
differences in EORTC QLQ-C30 quality of life function or
symptom scores. However, there were major differences in quality
of life and symptom scores with increasing stage of disease. In
particular, social functioning, fatigue, appetite loss and global
quality of life were all impaired with increasing tumour stage.
As might be expected in view of these associations with tumour
stage, the majority of quality of life and symptom scores predicted
survival on univariate analysis. It was of interest, however, that
Table 4 The relationship between appetite loss, clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer (n¼152)
Not at all (n¼55) A little (n¼43) Quite a bit (n¼26) Very much (n¼28) P-value
Age: (o65 years/ 65–74 years/X75 years) 27/18/10 18/15/10 8/15/3 13/8/7 0.540
Sex: (male/female) 43/12 26/17 15/11 20/8 0.312
Tumour type: (squamous/adeno) 7/48 5/38 7/19 6/22 0.138
Tumour site: (oesophagus/gastric) 25/30 17/26 15/11 13/15 0.603
Tumour length: (o5cm/5–10cm/ 410cm) 27/20/4 18/21/2 9/15/2 6/14/4 0.016
TNM stage: (I/II/III/IV) 16/17/13/8 8/17/9/9 3/8/7/8 1/4/5/16 o0.001
Weight loss: (yes/no) 26/29 27/16 22/4 26/2 o0.001
Dysphagia score: (1/2/3/4/5) 37/10/6/2/0 24/6/10/3/0 9/4/9/3/1 11/3/7/7/0 o0.001
ECOG: (0–1/2/3–4) 39/14/2 34/8/1 18/7/1 17/9/2 0.281
Treatment: (operable/inoperable) 35/20 20/23 11/15 3/25 o0.001
EORTC QLQ-C30 (0–100) Median (range) Median (range) Median (range) Median (range)
Physical functioning 100 (73.3–100) 100 (73.3–100) 86.7 (66.7–100) 80 (66.7–100) o0.001
Role functioning 100 (0–100) 66.7 (0–100) 58.3 (0–100) 33.3 (0–100) o0.001
Emotional functioning 75 (73.3–100) 66.7 (0–100) 83.3 (8.3–100) 58.3 (0–96.7) 0.003
Cognitive functioning 83.3 (16.7–100) 83.3 (0–100) 83.3 (50–100) 66.7(0–100) 0.001
Social functioning 100 (0–100) 83.3 (0–100) 66.7 (0–100) 50 (0–100) o0.001
Global quality of life 66.7 (16.7–100) 50 (0–100) 45.8(16.7–100) 29.1 (0–66.7) o0.001
Fatigue 11.1 (0–88.9) 33.3 (0–83.2) 33.3 (0–100) 77.7 (22.2–100) o0.001
Nausea and vomiting 0 (0–100) 16.7 (0–100) 16.7 (0–100) 41.7 (0–100) o0.001
Pain 16.7 (0–100) 16.7 (0–83.3) 33.3 (0–100) 25 (0–100) o0.001
Dyspnoea 0 (0–66.7) 0 (0–100) 0 (0–100) 50 (0–100) o0.001
Sleep disturbance 0 (0–100) 33.3 (0–100) 33.3 (0–100) 33.3 (0–100) 0.044
Constipation 0 (0–100) 33.3 (0–100) 33.3 (0–100) 66.7 (0–100) o0.001
Diarrhoea 0 (0–100) 0 (0–66.7) 0 (0–100) 0 (0–100) 0.512
Financial difficulty 0 (0–66.7) 0 (0–100) 0 (0–100) 0 (0–100) 0.296
Table 5 The relationship between systemic inflammatory response, as evidenced by elevated C-reactive protein, clinico-pathological and quality of life
characteristics in patients with gastric-oesophageal cancer (n¼94)
CRPo10 (n¼57) CRP410 (n¼37) P-value
Age: (o65 years/65–74 years/X75 years) 34/16/7 18/12/7 0.258
Sex: (male/female) 38/19 27/10 0.520
Tumour type: (adeno/squamous) 48/9 30/7 0.695
Tumour site: (oesophagus/gastric) 23/34 20/17 0.195
Tumour length: (o5cm/5–10cm/410cm) 35/17/2 11/20/3 0.005
Tumour stage: (I/II/III/IV) 15/20/13/8 4/10/10/13 0.006
Weight loss: (yes/no) 31/16 27/10 0.072
Dysphagia score: (1/2/3/4/5) 29/14/11/3/0 18/6/10/2/1 0.390
ECOG: (0–1/2/3–4) 52/5/0 27/10/0 0.019
Treatment: (operable/inoperable) 40/17 8/29 o0.001
EORTC: (0–100) Median (range) Median (range)
Physical functioning 100 (73–100) 86.7 (66.7–100) 0.001
Role functioning 66.7 (0–100) 66.7 (0–100) 0.040
Emotional functioning 66.7 (0–100) 70.8 (0–100) 0.343
Cognitive functioning 83.3 (16.7–100) 83.3 (33.3–100) 0.875
Social functioning 83.3 (0–100) 66.7 (0–100) 0.045
Global quality of life 66.7 (0–100) 50 (0–100) 0.068
Fatigue 33.3 (0–100) 44.4 (0–88.9) 0.003
Nausea and vomiting 16.7 (0–100) 16.7 (0–100) 0.152
Pain 16.7 (0–100) 16.7 (0–100) 0.040
Appetite loss 33.3 (0–100) 66.7 (0–100) 0.001
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factor even after adjustment for TNM stage and treatment.
Furthermore, the predictive value of appetite loss was maintained
even after adjustment for all other clinico-pathological variables
and quality of life and symptom scores. Taken together the results
of the present study highlight the importance of appetite loss as a
presenting symptom in patients with gastro-oesophageal cancer.
Few studies have examined the relationship between aspects of
quality of life and survival in patients with gastro-oesophageal
cancer. The results of the present study are consistent with the
report of Fang et al (2004) who reported that appetite loss was
associated with poorer survival in 110 patients with oesophageal
cancer. However, the association was much weaker than that of the
present study and was not significant in multivariate analysis.
Furthermore, the follow-up period and the number of patients who
died of their disease were not defined. Blazeby et al (1995), in a
smaller study of 59 patients with oesophageal cancer, also reported
that appetite loss was associated with poorer survival.
The basis of the relationship between appetite loss and poorer
cancer-specific survival cannot be determined by the present cross
sectional study. However, it was of interest that appetite loss was
closely associated with nausea and vomiting, dysphagia and weight
loss and therefore it may be that these symptoms result in appetite
loss and the consequent loss of weight, which has long been
recognised to impact on outcome (Dewys et al, 1980).
A number of workers have implicated the systemic inflamma-
tory response in this process (Kotler, 2000; MacDonald, 2007).
O’Gorman et al (1988), in a cross sectional study, showed that in
addition to appetite loss and weight loss, the systemic inflamma-
tory response was an important factor in determining patients’
quality of life (EORTC QLQ-C30) in gastro-intestinal cancer
patients (O’Gorman et al, 1988). Therefore, it is of interest that
two recent studies have shown that the presence of a systemic
inflammatory response, as evidenced by an elevated C-reactive
protein, predicts survival in both operable (Crumley et al, 2006a)
and inoperable (Crumley et al, 2006b) gastro-oesophageal cancer
patients. In the present study C-reactive protein concentrations, at
the time of quality of life assessment, were available in 94 (62%)
patients. Consistent with previous work an elevated C-reactive
protein concentration was associated with increased appetite loss
and when included in the multivariate analysis, an elevated
C-reactive protein concentration was independently associated
with poorer cancer-specific survival. However, even those patients
without an elevated C-reactive protein concentration reported
some appetite loss and the independent prognostic value of
appetite loss remained, thus confirming the importance of appetite
loss in the multifactorial nature of weight loss and poor outcome in
these patients (MacDonald, 2007).
In summary, in patients with gastro-oesophageal cancer,
routinely used prognostic factors are based predominantly
on clinical and pathological findings. The present study
highlights the importance of quality of life (EORTC QLQ-C30)
measures, in particular appetite loss, as prognostic factors in these
patients.
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